Breaking News, Collaborations & Alliances

Amphastar, Hanxin Enter Exclusive License Agreement for AMP-110

AMP-110 is a fully synthetic and highly purified analog of adrenocorticotropic hormone (ACTH), also known as corticotropin.

Author Image

By: Charlie Sternberg

Associate Editor

Amphastar Pharmaceuticals Inc. has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co. Ltd. for the development, and commercialization of fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs, now designated AMP-110, in the United States and Canada. AMP-110 is designed to address inflammatory and autoimmune conditions with a potentially improved safety profile compared to porcine-derived ACTH products. It is currently in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters